Exelixis stock just gave investors a jolt. The shares closed down almost 8% at US$52.20, even though the company printed another quarter of solid oncology profits. Q2 revenue came in at about US$628.7 million and net income reached roughly US$212 million, keeping the cabozantinib cash engine firmly running.

The tension for you now is time horizon. Short term traders are reacting to the trimmed full year revenue guidance. Long term holders will be looking at the higher net profit margin and richer trailing earnings base and asking whether this pullback resets the entry point for a multi year oncology story.

Is Exelixis now a rare case of fast growing earnings being priced like a slow grower, or is the trimmed guidance a red flag the market sees first? Compare the current multiples and implied upside in our valuation analysis for Exelixis

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$628.69 million vs. US$568.26 million (up around 10.6%)
• Net Income, Q2 2026 vs. Q2 2025: US$212.05 million vs. US$184.85 million (up around 14.7%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.85 vs. US$0.68 (up around 24.7%)
• Trailing 12 month Net Profit Margin, Q2 2026 vs. Q2 2025: 35.3% vs. 27.0% (margin higher year over year)

Prefer clean visual charts instead of another wall of earnings tables and guidance headlines? See Exelixis' full financial picture, including a clear view of its valuation, in the interactive company report for Exelixis.

Evaluating Whether Exelixis Is Truly Becoming Multi Franchise

The bullish story around Exelixis is that cabozantinib funds a shift to a broader oncology portfolio anchored by zanzalintinib, without losing commercial momentum or financial flexibility. Q2 results show meaningful milestones against that script. Cabozantinib U.S. net product revenue and global franchise revenue both moved higher year over year, and prescription share in the oral TKI basket reached 47%. That supports the idea that the current flagship is still doing the heavy lifting.

On diversification, zanzalintinib is now past the “concept” stage. The NDA in metastatic colorectal cancer is under FDA review with a December PDUFA date, STELLAR‑304 and STELLAR‑311 are on track for H2 2026 readouts, and enrollment for the NET Phase III is running ahead of plan. Cash and securities of about US$1.4b plus ongoing buybacks indicate the balance sheet is still supporting both pipeline and capital returns.

Reveal where the surface looks calm, but the street models start to diverge. Access the full multi year revenue and earnings analyst estimates for Exelixis

Exelixis Bear Concerns Shift From Theory To Timelines

The bearish story on Exelixis is that heavy reliance on cabozantinib, rising gross to net pressure and high execution risk leave little room for disappointment. This quarter gives that view some traction. Management cut the full year revenue midpoint by about US$50 million and raised the 2026 gross to net outlook for cabozantinib to 30% to 31%. That ties directly to concerns about payer pressure and discount creep. The slower than expected neuroendocrine tumor ramp means diversification is arriving later than hoped, not earlier.

Concentration risk is also still front and center. Cabozantinib franchise revenue remains the clear profit engine while zanzalintinib is still pre approval. With the stock down almost 8% on the day and guidance trimmed, the view that execution misses can trigger outsized share price moves appears reinforced, even though free cash flow and the balance sheet remain intact.

Scan Exelixis for hidden execution and concentration risks that guidance cuts alone might not reveal by reading the risk analysis for Exelixis which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If the mix of solid Q2 profits, trimmed guidance and an 8% one day move in Exelixis has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and be ready when the entry point looks right. After you take a position, keep your focus with the Portfolio Command Center that highlights only the most important changes affecting your holdings and filters out day to day noise. For a longer term view, join the Community to see how other investors are interpreting the same earnings, guidance shifts and risk signals. By spotting potential catalysts and risks early, you give yourself a better chance to stay ahead of the market and act with confidence.

Seeking Alternatives Beyond Exelixis?

Fresh stock ideas can move from quiet to breakout fast. Use the screener while signals still matter and prices have not fully caught new momentum. Get in early.

• Target durable income streams by scanning curated 8 dividend fortresses that aim to keep portfolios flying higher on reliable cash returns while others chase short term stories.
• Hunt for resilient growth by reviewing 77 resilient stocks with low risk scores before the crowd notices their steady momentum and the best entry points are caught and gone.
• Spot under the radar growth potential with 19 high quality undiscovered gems while these fresh ideas are still quietly building, not yet priced for a full breakout.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.